Aflibercept: all 271 studies that test it
Page 2 of 3. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical ImpactCompletedNCT00789477Phase 2Results posted
- Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine TherapyCompletedNCT00729157Phase 2Results posted
- Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)CompletedNCT00637377Phase 3Results posted
- Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic CancerTerminatedNCT00574275Phase 3Results posted
- Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based RegimenCompletedNCT00561470Phase 3Results posted
- A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT00532155Phase 3Results posted
- Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate CancerCompletedNCT00519285Phase 3Results posted
- Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)CompletedNCT00509795Phase 3Results posted
- Aflibercept in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00509249Phase 2Results posted
- VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00462826Phase 2Results posted
- VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00450255Phase 2Results posted
- Aflibercept for Relapsed Multiple MyelomaTerminatedNCT00437034Phase 2Results posted
- VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT00407654Phase 2Results posted
- VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the UrotheliumCompletedNCT00407485Phase 2Results posted
- AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant AscitesCompletedNCT00396591Phase 2Results posted
- Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue SarcomaCompletedNCT00390234Phase 2Results posted
- VEGF Trap in Treating Patients With Metastatic Breast CancerCompletedNCT00369655Phase 2Results posted
- VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to TemozolomideCompletedNCT00369590Phase 2Results posted
- Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00357760Phase 2Results posted
- Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant AscitesCompletedNCT00327444Phase 2/3Results posted
- Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian CancerCompletedNCT00327171Phase 2Results posted
- Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)CompletedNCT00320788Phase 2Results posted
- Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung AdenocarcinomaCompletedNCT00284141Phase 2Results posted
- A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular OedemaCompletedNCT07844343Phase 2
- Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic RetinopathyCompletedNCT07501052Phase 2
- High Dose Eylea for Proliferative Diabetic Retinopathy OutcomesActive, not recruitingNCT07118670Phase 4
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular EdemaCompletedNCT06850922Phase 1/2
- A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)Active, not recruitingNCT06817343Phase 1
- Ocular Safety and Usability Study for FYB203 PFSCompletedNCT06708637Phase 4
- Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous TreatmentCompletedNCT06683950Phase 4
- A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular DegenerationCompletedNCT06591598Phase 4
- A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular EdemaCompletedNCT06422507Phase 3
- Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein OcclusionCompletedNCT06416241Phase 4
- Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual AcuityCompletedNCT06330220Phase 4
- Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein OcclusionCompletedNCT06146309Not applicable
- Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular DegenerationCompletedNCT05587062Phase 3
- A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)CompletedNCT05345236Phase 3
- Ranibizumab Versus Aflibercept for CRVO in Young Patients.Status unknownNCT05282420Phase 4
- Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)CompletedNCT05155293Phase 3
- Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular GlaucomaCompletedNCT04970251Not applicable
- Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMDActive, not recruitingNCT04932980Not applicable
- Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA TrialCompletedNCT04708145Phase 4
- Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving AfliberceptStatus unknownNCT04707027Not applicable
- Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the EyeWithdrawnNCT04702048Phase 4
- Treat-and-extend Using Aflibercept for Type 3 NeovascularizationStatus unknownNCT04655482Phase 4
- A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular EdemaWithdrawnNCT04588948Phase 2
- Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment RepairStatus unknownNCT04580147Phase 2
- Use of Ziv Aflibercept in Different Retinal DiseasesCompletedNCT04290195Phase 1/2
- Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in TaiwanCompletedNCT04288232Phase 3
- Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous HemorrhageCompletedNCT04153253Phase 4
- Treat and Extend Analysis Trial With Aflibercept in Wet-AMDStatus unknownNCT04113538Phase 3
- Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)CompletedNCT04087746Phase 4
- Treatment of Polypoidal Choroidal Vasculopathy in PachychoroidCompletedNCT04075188Not applicable
- Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090CompletedNCT04015180Phase 3
- One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to BevacizumabCompletedNCT03974425Not applicable
- Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV TreatmentCompletedNCT03941587Not applicable
- Cataract DME - Peri vs. IntraopWithdrawnNCT03920878Phase 2
- Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1TerminatedNCT03845049Phase 3
- Effect Aflibercept on Ocular PerfusionCompletedNCT03804099Phase 4
- Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT)CompletedNCT03780361Phase 4
- Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.CompletedNCT03766425Early Phase 1
- Eylea and Lucentis for Macular Edema in Branch Retinal Vein OcclusionCompletedNCT03709745Phase 4
- Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular EdemaWithdrawnNCT03629210Phase 2
- Intense Treatment Regimen With Intravitreal Aflibercept InjectionStatus unknownNCT03594461Phase 1/2
- Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy ImprovementCompletedNCT03531294Phase 2
- Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly AfliberceptStatus unknownNCT03468296Phase 4
- Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept InjectionCompletedNCT03453281Phase 4
- Ziv-aflibercept Efficacy in Better Regulating AMDCompletedNCT03423823Phase 2
- Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein OcclusionStatus unknownNCT03405376Phase 4
- Treatment of Macular Edema After Cataract Surgery with Subconjunctival AfliberceptTerminatedNCT03396861Phase 1
- ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)WithdrawnNCT03374670Phase 2
- Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based RegimenCompletedNCT03279289Phase 2
- Trial of Aflibercept Monotherapy With DCE-US in Chemorefractory Metastatic Colorectal CancerWithdrawnNCT03264274Phase 2
- Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DMEStatus unknownNCT03197480Phase 4
- Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal MelanomaCompletedNCT03172299Phase 3
- Intravitreal Aflibercept for Submacular HemorrhageCompletedNCT03169660Phase 4
- Intravitreal Aflibercept Injection for Radiation Retinopathy TrialStatus unknownNCT03085784Phase 2
- Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal RanibizumabWithdrawnNCT03059277Phase 4
- Cytokine and Visual Outcome Variations in Eyes Receiving AfliberceptStatus unknownNCT03056079Phase 4
- mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal CancerCompletedNCT03043729Phase 2
- The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic RetinopathyCompletedNCT03006081Phase 2
- Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VHStatus unknownNCT02976012Phase 1/2
- Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE PolymorphismsCompletedNCT02970916Phase 2
- Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular EdemaStatus unknownNCT02924987Phase 4
- 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.WithdrawnNCT02878681Phase 4
- Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal NeovascularizationTerminatedNCT02797704Phase 1/2
- Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)Status unknownNCT02788877Phase 4
- 3 Month Outcome of Ziv-aflibercept for DMECompletedNCT02772497Phase 2/3
- Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular EdemaCompletedNCT02734407Phase 4
- PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLiberceptStatus unknownNCT02681783Phase 4
- Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective StudyStatus unknownNCT02651168Phase 4
- Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular EdemaCompletedNCT02646670Phase 4
- The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular EdemaStatus unknownNCT02645734Phase 2/3
- Mean Visual Acuity Changes Following Five Injections of AfliberceptActive, not recruitingNCT02645266Not applicable
- Intravitreal Aflibercept or Ranibizumab for Rubeosis IridisCompletedNCT02641457Phase 3
- Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular EdemaCompletedNCT02633852Phase 4
- Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioNStatus unknownNCT02630277Phase 2
- Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line TreatmentStatus unknownNCT02624726Phase 2
- Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).WithdrawnNCT02573038Phase 2
- Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).CompletedNCT02556229Phase 2